세계의 동물용 신경 퇴행성 질환 진단 시장 : 제품 유형별, 진단 테스트별, 동물 유형별, 적응증별, 최종 용도별, 지역별 - 기회 및 예측(2018-2032년)

Global veterinary neurodegenerative disease diagnostics market is projected to witness a CAGR of 7.47% during the forecast period 2025-2032, growing from USD 0.40 billion in 2024 to USD 0.71 billion in 2032. The veterinary neurodegenerative disease diagnostics market continues to grow in a consistent manner, partially due to the increase in awareness of neurological disorders in animals and the need for early and accurate diagnostics. Many innovations in diagnostics have great significance and relevance to veterinary medicine, such as artificial intelligence-assisted imaging, portable imaging in the form of MRI, and molecular biomarker assessments. This is significantly changing the ways in which veterinarians detect, monitor and assess complex diseases in companion animals including cognitive dysfunction. Increased levels of pet ownership and the emotional bond that people have with their companion animals also influence the increased spending for specialty care.

Additionally, the expansion of pet insurance and government-supported livestock insurance schemes is reducing cost-related barriers and enabling wider access to advanced diagnostics. Continuous technological innovation, combined with growing investment in veterinary research and improved clinical infrastructure, plays a vital role in shaping the future of this evolving market.

For instance, in October 2024, WOORIEN Co., Ltd. launched the MyVet CT Plus, a spiral-linear veterinary CT scanner featuring significantly faster scan and reconstruction times-reducing acquisition by up to 80%-and a flexible field-of-view suitable for animals from small reptiles to large dogs, making advanced imaging more accessible to diverse veterinary practices

Advancements in Diagnostic Technologies Driving Precision in Veterinary Neurodegenerative Disease Diagnostics

Veterinary neurodegenerative diagnostics is rapidly evolving with the integration of advanced technologies. Newer technologies, such as AI based imaging, high field MRI, and biomarker-based testing, will lead to earlier and more precise identification of complex neurological problems. In addition to offering more precise identification of disease, these technologies also provide improved characterization of the disease, assist with planning treatment, and provide ongoing assessment of treatment efficacy. The transition to digital systems and point-of-care diagnostics will enhance accessibility to diagnostics in all aspects of veterinary practice ranging from no/vet to urban/rural contexts. Advanced imaging, specifically MRI has evolved significantly in its ability to assess and identify subtle brain and spinal abnormalities. The ability progressively to document and assess a patient's disease over time will provide the veterinary clinician with substantial insights into disease progression and prognosis. Advances in technology are changing the landscape of veterinary neurology.

For instance, in June 2025, Siemens Healthineers gained FDA clearance for the Magnetom Flow.Ace 1.5 T MRI scanner, developed for both human and veterinary applications. Featuring AI-powered image reconstruction and an energy-efficient CoolDry helium system, the scanner enhances soft-tissue visualization, shortens scan durations, and adapts to diverse animal anatomies, marking a significant advancement in veterinary neurodiagnostic imaging.

Growing Pet Insurance Coverage Fuels Market Expansion

The increasing availability and uptake of pet insurance is one of the most important factors contributing to the growth of the veterinary neurodegenerative disease diagnostics market. Because diagnostic tools like MRIs, CTs, and biomarker tests can be expensive, insurance coverage opens up options for clients without the affordability barrier. Many policies now cover advanced diagnostic services; thus, veterinarians can now recommend full neurological evaluations without excess financial concern. This not only helps pet owners get an early and accurate diagnostic outcome when assessing if neurodegenerative disease is present, insurance had also opened the gate for veterinarians to adopt advanced technology by providing the immediate financial support necessary. The financial resources from insurance have quickened the pace of precision diagnostics and is helping to shape the future of the market.

For instance, in March 2025, according to Press Information Bureau, Government of India Under the National Livestock Mission (NLM), 21.01 lakh livestock animals were insured in the current financial year, supporting access to veterinary diagnostics, including neurodegenerative disease detection, by reducing financial barriers for farmers through demand-driven insurance coverage.

MRI Imaging Leads in Veterinary Neurodegenerative Diagnostics Market

MRI has emerged as the leading diagnostic tool in the veterinary neurodegenerative diagnostics market. As a non-invasive imaging technique, MRI excels at producing high-quality images of the brain and spinal cord, allowing for the identification of various conditions, regardless of their etiology, including cognitive dysfunction, cerebellar abiotrophy and other neurodegenerative diseases. MRI is set apart from other imaging techniques by its exceptional soft tissue contrast and absence of radiation exposure, making it a safer proposition. As a result, veterinary clinics and specialty hospitals are installing MRI systems into their practices to allow for rapid and accurate assessment of animals. The increase in demand for advanced neurological diagnostic testing provided to companion animals (dogs and cats) has further justified the use of MRI in a veterinary setting. With improved technology and availability of high-field MRI systems, this segment continues to gain momentum within the veterinary imaging market.

For instance, in October 2024, InkSpace Imaging LLC introduced the Nuzzle veterinary array, a new and innovative MRI coil that is approved for animal use. This will allow for much clearer, high-resolution images to drive detection and diagnosis of neurological diseases and disorders in the field of veterinary medicine.

North America Leads the Veterinary Neurodegenerative Diagnostics Market

North America holds a dominant position in the veterinary neurodegenerative diagnostics market. The main reason behind this is its well-developed veterinary healthcare system and high awareness among pet owners regarding neurological conditions in animals. The North America region is generally characterized by strong research and development funding, robust regulatory frameworks, strong veterinary healthcare systems, partnerships between academia, diagnostic developers, and commercialization support. The North America region has a large population of companion and performance animals along with an abundance of skilled veterinary professionals. The overall focus of North America is on the early and accurate detection of disease, and it has so far supported and sustained all the necessary elements to lead the way in veterinary neurodegenerative diagnostics.

For instance, in March 2025, NVIDIA Corporation and GE HealthCare Technologies Inc. announced a partnership to develop autonomous diagnostic imaging systems using physical AI. This collaboration leverages simulation and robotics to improve imaging accuracy and efficiency in clinical settings.

Impact of U.S. Tariffs on Veterinary Neurodegenerative Disease Diagnostics Market

Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.

Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries. Companies may select to work with domestic suppliers or alternate suppliers, which affect time.

Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.

Higher prices and lower availability may inhibit any growth of the market in the interim time.

Key Players Landscape and Outlook

The key players operating the market are focusing on innovation, strategic partnerships, and continuing advancements in diagnostics. Their priority is to the develop improved tools for the early detection of neurodegenerative diseases in the veterinary setting. Most of the companies are investing in artificial intelligence and digital image assessment tools to improve accuracy and efficiency of diagnostics. Others are emphasizing point-of-care testing to provide rapid diagnostics in a clinical environment. Many are emphasizing the expansion of laboratory networks as well as the integration of diagnostics with the treatment protocols. Other companies are partnering with research institutions to assess new biomarkers and neuroimaging. The greater usage of cloud-based diagnostic resources is expediting diagnostic workflows and promoting processes that allow data transfer sharing. Thus, the focus is on technological advancement, accessibility, and achieving better diagnostic decisions about difficult neurodegenerative issues in animals.

For instance, in January 2025, Zoetis Inc. launched an enhanced Vetscan Imagyst with 6-in-1 AI-powered diagnostics, including blood, fecal, dermatology, and urine analysis, advancing speed and accuracy in veterinary neuro diagnostics.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product Type
    • 5.2.1.1. Consumables, Reagents, and Kits
    • 5.2.1.2. Equipment and Instruments
  • 5.2.2. By Diagnostic Tests
    • 5.2.2.1. Imaging
      • 5.2.2.1.1. MRI (Magnetic Resonance Imaging)
      • 5.2.2.1.2. CT (Computed Tomography)
      • 5.2.2.1.3. Others
    • 5.2.2.2. Biomarker Diagnostic Tests
      • 5.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
      • 5.2.2.2.2. Blood-based Biomarkers
      • 5.2.2.2.3. Others
    • 5.2.2.3. Others
  • 5.2.3. By Animal Type
    • 5.2.3.1. Livestock
      • 5.2.3.1.1. Sheep
      • 5.2.3.1.2. Cattle
      • 5.2.3.1.3. Others
    • 5.2.3.2. Companion
      • 5.2.3.2.1. Canine
      • 5.2.3.2.2. Feline
      • 5.2.3.2.3. Equine
      • 5.2.3.2.4. Others
  • 5.2.4. By Indication
    • 5.2.4.1. Cognitive Dysfunction
    • 5.2.4.2. Cerebellar Abiotrophy
    • 5.2.4.3. Spongiform Encephalopathies
    • 5.2.4.4. Others
  • 5.2.5. By End-Use
    • 5.2.5.1. Veterinary Hospitals and Clinics
    • 5.2.5.2. Veterinary Diagnostic Laboratories
    • 5.2.5.3. Others
  • 5.2.6. By Region
    • 5.2.6.1. North America
    • 5.2.6.2. Europe
    • 5.2.6.3. Asia-Pacific
    • 5.2.6.4. South America
    • 5.2.6.5. Middle East and Africa
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product Type
  • 5.3.2. By Diagnostic Tests
  • 5.3.3. By Animal Type
  • 5.3.4. By Indication
  • 5.3.5. By End-Use
  • 5.3.6. By Region

6. North America Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Product Type
    • 6.2.1.1. Consumables, Reagents, and Kits
    • 6.2.1.2. Equipment and Instruments
  • 6.2.2. By Diagnostic Tests
    • 6.2.2.1. Imaging
      • 6.2.2.1.1. MRI (Magnetic Resonance Imaging)
      • 6.2.2.1.2. CT (Computed Tomography)
      • 6.2.2.1.3. Others
    • 6.2.2.2. Biomarker Diagnostic Tests
      • 6.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
      • 6.2.2.2.2. Blood-based Biomarkers
      • 6.2.2.2.3. Others
    • 6.2.2.3. Others
  • 6.2.3. By Animal Type
    • 6.2.3.1. Livestock
      • 6.2.3.1.1. Sheep
      • 6.2.3.1.2. Cattle
      • 6.2.3.1.3. Others
    • 6.2.3.2. Companion
      • 6.2.3.2.1. Canine
      • 6.2.3.2.2. Feline
      • 6.2.3.2.3. Equine
      • 6.2.3.2.4. Others
  • 6.2.4. By Indication
    • 6.2.4.1. Cognitive Dysfunction
    • 6.2.4.2. Cerebellar Abiotrophy
    • 6.2.4.3. Spongiform Encephalopathies
    • 6.2.4.4. Others
  • 6.2.5. By End-Use
    • 6.2.5.1. Veterinary Hospitals and Clinics
    • 6.2.5.2. Veterinary Diagnostic Laboratories
    • 6.2.5.3. Others
  • 6.2.6. By Country Share
    • 6.2.6.1. United States
    • 6.2.6.2. Canada
    • 6.2.6.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Product Type
        • 6.3.1.2.1.1. Consumables, Reagents, and Kits
        • 6.3.1.2.1.2. Equipment and Instruments
      • 6.3.1.2.2. By Diagnostic Tests
        • 6.3.1.2.2.1. Imaging
        • 6.3.1.2.2.1.1. MRI (Magnetic Resonance Imaging)
        • 6.3.1.2.2.1.2. CT (Computed Tomography)
        • 6.3.1.2.2.1.3. Others
        • 6.3.1.2.2.2. Biomarker Diagnostic Tests
        • 6.3.1.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
        • 6.3.1.2.2.2.2. Blood-based Biomarkers
        • 6.3.1.2.2.2.3. Others
        • 6.3.1.2.2.3. Others
      • 6.3.1.2.3. By Animal Type
        • 6.3.1.2.3.1. Livestock
        • 6.3.1.2.3.1.1. Sheep
        • 6.3.1.2.3.1.2. Cattle
        • 6.3.1.2.3.1.3. Others
        • 6.3.1.2.3.2. Companion
        • 6.3.1.2.3.2.1. Canine
        • 6.3.1.2.3.2.2. Feline
        • 6.3.1.2.3.2.3. Equine
        • 6.3.1.2.3.2.4. Others
      • 6.3.1.2.4. By Indication
        • 6.3.1.2.4.1. Cognitive Dysfunction
        • 6.3.1.2.4.2. Cerebellar Abiotrophy
        • 6.3.1.2.4.3. Spongiform Encephalopathies
        • 6.3.1.2.4.4. Others
      • 6.3.1.2.5. By End-Use
        • 6.3.1.2.5.1. Veterinary Hospitals and Clinics
        • 6.3.1.2.5.2. Veterinary Diagnostic Laboratories
        • 6.3.1.2.5.3. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Case Studies

19. Competitive Landscape

• 19.1. Competition Matrix of Top 5 Market Leaders
• 19.2. SWOT Analysis for Top 5 Players
• 19.3. Key Players Landscape for Top 10 Market Players
  • 19.3.1. Zoetis Inc.
    • 19.3.1.1. Company Details
    • 19.3.1.2. Key Management Personnel
    • 19.3.1.3. Products and Services
    • 19.3.1.4. Financials (As Reported)
    • 19.3.1.5. Key Market Focus and Geographical Presence
    • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 19.3.2. Virbac SA
  • 19.3.3. Life Diagnostics, Inc.
  • 19.3.4. ACUVET Biotech
  • 19.3.5. Merck Animal Health (Merck & Co., Inc.)
  • 19.3.6. IDEXX Laboratories, Inc.
  • 19.3.7. MI:RNA Diagnostics Ltd.
  • 19.3.8. Mercodia AB
  • 19.3.9. Antech Diagnostics, Inc.
  • 19.3.10. Avacta Animal Health Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer